LL-37 vs Thymosin Alpha-1
Both LL-37 and Thymosin Alpha-1 are used for immune and anti-inflammatory. Here's how their evidence, dosing, and regulatory status actually compare.
LL-37
Evidence BCathelicidin LL-37
The only human cathelicidin antimicrobial peptide. Active against bacteria, viruses, and biofilms. Investigated topically for infected wounds and mucosal infections.
View full LL-37 profile →Thymosin Alpha-1
Evidence AThymosin Alpha-1 (Tα1)
A 28-amino-acid thymic peptide that matures and modulates T-cells. Used internationally as an adjunct in hepatitis, sepsis, and immune-compromised cancer care.
View full Thymosin Alpha-1 profile →Side-by-Side
| Attribute | LL-37 | Thymosin Alpha-1 |
|---|---|---|
| Evidence Grade | B | A |
| FDA Status | Not FDA-approved — endogenous antimicrobial peptide; clinical trials for infected wounds | Approved in 35+ countries for hepatitis B/C, immune support; not FDA-approved in US (orphan-drug designations) |
| Typical Dose | Trial range: topical or intralesional | 1.6 mg twice weekly (subcutaneous) |
| Clinics Indexed | 19 | 192 |
| Categories | immune, anti-inflammatory | immune, anti-inflammatory |
Key reported benefits — LL-37
- ✓Broad antimicrobial activity
- ✓Wound healing
- ✓Anti-biofilm
Key reported benefits — Thymosin Alpha-1
- ✓T-cell maturation
- ✓Antiviral immunity
- ✓Tumor immune support
- ✓Sepsis adjunct
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.